Key result
Anthracycline-based chemotherapy for LBCL linked to a ~116% higher 5-year risk of new-onset HF.
Why the study?
Patients with large B-cell lymphoma face an increased risk of heart failure, but associations with treatment intensity, heart failure subtype, and prognosis remain under-characterized.
Does treatment for large B-cell lymphoma increase the risk of new-onset heart failure compared to matched population comparators?
Cohort (n=79,959)
Yes
Does treatment for large B-cell lymphoma increase the risk of new-onset heart failure compared to matched population comparators?
Answers are grounded in this paper and cite their sources.
Patients treated for large B-cell lymphoma face a sustained, two-fold increased long-term risk of new-onset non-ischemic heart failure compared to the general population, emphasizing the need for vigilant survivorship screening.
Patients with large B-cell lymphoma (LBCL) are at increased risk of heart failure (HF) potentially due to anthracycline-based chemotherapy. However, associations with LBCL treatment intensity, HF subtype, and outcome remain under-characterized. We conducted a nationwide cohort study of 8,453 Swedish patients diagnosed with LBCL (median age 70 years) between 2007-2022 and 71,506 matched population comparators without a history of HF. The 5-year cumulative incidence of new-onset HF among patients was 8.1% overall, corresponding to a two-fold increased rate, driven mainly by non-ischemic HF (hazard ratio [HR]non-ischemic 2.33, 95% confidence interval [CI] 2.16-2.50), and less by ischemic HF (HRischemic 1.30, 95% CI 1.04-1.62). An increased rate of new-onset non-ischemic HF remained after 2 years of follow-up (HR 1.78, 95% CI 1.60-1.94). Few patients had reduced-intensity treatment (4 R-CHOP, n=84) of whom none developed HF. Patients selected for intensive treatment (e.g., R-CHOEP/R-DA-EPOCH) were not at higher risk of HF compared with standard R-CHOP (HR 0.73, 95% CI 0.58-0.92), although unmeasured differences in baseline fitness or frailty may have influenced treatment selection. After HF onset, LBCL patients had consistently higher all-cause (but not cardiovascular) mortality than comparators. Our findings indicate that LBCL patients face a sustained long-term risk of non-ischemic HF, highlighting the importance of survivorship care and vigilant HF symptom screening.
No takes yet. Share an insight, caveat, or question.
Godtfredsen et al. (2026) conducted a cohort in Large B-cell lymphoma (n=79,959). Large B-cell lymphoma vs. Matched population comparators without a history of heart failure was evaluated on New-onset non-ischemic heart failure (HR 2.33, 95% CI 2.16-2.50). Large B-cell lymphoma was associated with an 8.1% 5-year incidence of new-onset heart failure, driven primarily by an increased risk of non-ischemic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: